Rajeev Sir, you mentioned that it is taking slightly longer for the results to come. So is it about being more patient with the changes that you made? Or you need to make some more investments to bring the desired results?
Sure. And in your view, what are the pain points at this moment, where do you see these challenges? And how do you see the change happening in second half?
Yes, good afternoon, and thank you for taking my questions. So, Krishna, just to understand, for the CDMO business, for next year, the driver will be these existing products, or is there some new filing which has happened and you can see incremental growth from that?
And within those existing, is it that you become a preferred supplier now versus a secondary supplier earlier?
One question is on nutraceuticals. If the revenue for the quarter 178 crores, did I hear that correctly?
Was the revenue of Rs.178 crores in 1Q '24 as well?
Vivek, can you quantify the one time spent that you are going to incur in FY’25 on complex hospitals?
8% to 9, this includes everything, right?
Peter, on this new integrated order for ADC , so can you tell us which stage is this order -- is it stage-III or NDA filing or commercial?
Peter, the company has over the years built multiple capabilities. ADC is one, there is Hypo APIs, peptides, control substances. So , which are the areas that excite you, where is Piramal differentiated has an edge over others and that can be a significant growth driver for CDMO say over the next three, five years?
Okay, sir. Thank you, Mr. Lalit. Yes, that's it from my side. Thank you.. Moderator: Thank you. The next question is on the line of Monish Shah from Antique Stock Broking. Please go ahead. Monish Shah: Yes. Hi. Thank you for the opportunity. Sir, just a question on the existing products. Amongst our key products like Tacrolimus, cyclosporine, and everolimus, there are different dosage forms, like an extended release or a gel or a solution, which is going off patent next year and, you know, a couple of years after. So, just wanted to check, does that give us a sizable opportunity from generic entry standpoint? Ankur Vaid: Yes, that does. And we are working with several customers for such kind of new formulations as well. Monish Shah: Okay. And that drives your revenue guidance? I mean, that is a sizable part of revenue guidance? Ankur Vaid: So, it will all depend in terms of how the generic players kind of get into the products once it becomes generic. So, when we talk about the overall guidance over the next four years to five years, such kind of opportunities have been built into that. Monish Shah: Okay. Got it. Yes, that is it from my side. Thank you.